The efficacy and safety of Dl-3n-butylphthalide on progressive cerebral infarction: A randomized controlled STROBE study

• Published in: Medicine (Baltimore) Vol. 96; no. 30; p. e7257
• Main Authors: Zhang, Chenhao, Zhao, Shuqin, Zang, Yanjing, Gu, Fang, Mao, Shufang, Feng, Shanshan, Hu, Lei, Zhang, Chunliang
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.07.2017
• Subjects: Activities of Daily Living; Administration, Oral; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Benzofurans - adverse effects; Benzofurans - therapeutic use; Cerebral Infarction - drug therapy; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents - adverse effects; Neuroprotective Agents - therapeutic use; Observational Study; Severity of Illness Index; Time Factors; Treatment Outcome

Progressive cerebral infarction (PCI) is associated with high rates of mortality and disability. Many studies have shown that Dl-3n-butylphthalide (NBP) is effective against acute ischemic stroke. The administration of NBP can result in an increased number of capillaries in the ischemic region, prom...